Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: A prospective, multicenter phase 3 study

Blood

Volumn 115, Issue 10, 2010, Pages 1873-1879

  Palumbo, Antonio ^a   Bringhen, Sara ^a   Bruno, Benedetto ^a   Falcone, Antonietta Pia ^b   Liberati, Anna Marina ^c   Grasso, Mariella ^d   Ria, Roberto ^e   Pisani, Francesco ^f   Cangialosi, Clotilde ^g   Caravita, Tommaso ^h   Levi, Anna ⁱ   Meloni, Giovanna ⁱ   Nozza, Andrea ^j   Pregno, Patrizia ^k   Gabbas, Attilio ^l   Callea, Vincenzo ^m   Rizzo, Manuela ⁿ   Annino, Luciana ^o   De Stefano, Valerio ^p   Musto, Pellegrino ^q   Baldi, Ileana ^k   Cavallo, Federica ^a   Petrucci, Maria Teresa ⁱ   Massaia, Massimo ^a   Boccadoro, Mario ^a   more..

^a UNIVERSITY OF TURIN   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c POLICLINICO MONTELUCE   (Italy)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e POLICLINICO   (Italy)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^g VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^k CPO Piemonte   (Italy)

^l Ematologia Ospedale di Nuoro   (Italy)

^m Ospedale BiancoMelacrino Morelli   (Italy)

ⁿ TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^o SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^p CATHOLIC UNIVERSITY   (Italy)

^q REFERRAL CANCER CENTER OF BASILICATA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE COMPARISON; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS INFECTION; VOMITING;

EID: 77950421708     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-09-241737     Document Type: Article

References (23)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335(2):91-97. (Pubitemid 26240110)
2. Child JA, Morgan GJ, Davies FE, et al. High dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875-1883. (Pubitemid 36532313)
3. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104(10):3052-3057.
4. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502. (Pubitemid 38010075)
5. Goldschmidt H. Single vs double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial [abstract]. Haematologica. 2005;90[suppl 1]:38. Abstract PL8.02.
6. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood. 2002;99(3):731-735.
7. Palumbo A, Bringhen S, Bertola A, et al. Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/ m2). Leukemia. 2004;18(1):133-138. (Pubitemid 38159449)
8. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-854.
9. Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1464-1473.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc. 1958;53:457-481.
11. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34(2):187-220.
12. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia. 2009;23(3):449-456.
13. Attal M, Harousseau J-L, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335(2):91-97. (Pubitemid 26240110)
14. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood. 2002;99(3):731-735.
15. Kumar SK, Rajkumar S, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516-2520.
16. Harousseau JL. Induction therapy in multiple myeloma. Am Soc Hematol Educ Program. 2008;306-312.
17. Cavo M, Tacchetti P, Patriarca F, et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide- dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood. (ASH Annual Meeting Abstracts.) 2008;112. Abstract 158.
18. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91(11):1498-1505.
19. Harousseau JL, Mathiot C, Attal M, et al. VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantion (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial [abstract]. Blood. (ASH Annual Meeting Abstracts.) 2007;110. Abstract 450.
20. Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation- maintenance in untreated multiple myeloma patients. J Clin Oncol. 2010;28(5):800-807.
21. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354(10):1021-1030.
22. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-1218.
23. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24(6):929-936. (Pubitemid 46638847)